NewEdge Wealth’s Lexicon Pharmaceuticals LXRX Stock Holding History

NewEdge Wealth’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-42,418	Closed	-$249K	–	300
2021 Q1	$249K	Buy	+42,418	New	+$294K	0.02%	268

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NewEdge Wealth's LXRX Position: Q2 2021 in Review

NewEdge Wealth sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2021, closing a stake of 42,418 shares — an estimated $249K sold.

NewEdge Wealth first reported a position in LXRX in Q1 2021 and held it in 1 quarter. The position peaked at $249K in Q1 2021. 107 funds tracked by Wall St. Rank hold LXRX as of Q2 2021.

NewEdge Wealth reported no remaining Lexicon Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
NewEdge Wealth sold 42,418 Lexicon Pharmaceuticals shares in Q2 2021, an estimated $249K.
NewEdge Wealth first reported a position in Lexicon Pharmaceuticals in Q1 2021 and held it in 1 quarter.
NewEdge Wealth's Lexicon Pharmaceuticals position peaked at $249K in Q1 2021.
107 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2021.

Based on NewEdge Wealth's 13F filing for Q2 2021, filed 11 Aug 2021.